Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.
“I am delighted to be working with Isogenica on this research project. They are experts in the field of peptide engineering and their CIS-Display technology is ideal for screening NovaBiotic's vast library of anti-infective peptides as efficiently as possible and enabling NovaBiotics to fast-track the development of its product pipeline.”
As part of the agreement, NovaBiotics will work with Isogenica on two research projects, one concerning peptide selection and the other concerning peptide maturation with the aim of expanding Novabiotic's product portfolio.
Founded in 2000, Isogenica specialises in the discovery of therapeutic and diagnostic peptides and proteins using its proprietary technology CIS display, and has developed a unique capability in the field of peptide engineering. CIS display is an in vitro display technology that allows the rapid generation of polypeptide libraries of unprecedented size and complexity.
NovaBiotics' current product portfolio includes Novexatin®, a topical treatment for fungal nail infection which has recently completed Phase IIa clinical trials and Novamycin®, a candidate treatment for potentially life-threatening blood stream and deep tissue yeast and mould infections (predominantly Candida) which is expected to enter clinical development in 2011. In addition, NovaBiotics' antibacterial peptide drug candidates are now at the lead compound selection stage for both the treatment of respiratory infections including multi-drug resistant forms and deep tissue and skin infections including MRSA.
Kevin Matthews, CEO of Isogenica commented: "Following on from the successful antimicrobial project with Dstl, we are delighted that NovaBiotics have chosen Isogenica as their partner for these two projects. As a company we are focused on servicing the protein engineering needs of the pharmaceutical and biotech industries and as a result of such partnerships we are discovering highly active lead candidates for drug development."
Dr Deborah O'Neil, Founder of NovaBiotics, commented: "I am delighted to be working with Isogenica on this research project. They are experts in the field of peptide engineering and their CIS-Display technology is ideal for screening NovaBiotic's vast library of anti-infective peptides as efficiently as possible and enabling NovaBiotics to fast-track the development of its product pipeline."
NovaBiotics joins a growing list of leading pharmaceutical and biotech companies that have already partnered with Isogenica in the discovery of novel peptides for therapeutic and non-therapeutic applications or licenses, including Centocor, Pfizer, Dstl, Phylogica, and UCB.
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses